These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

750 related articles for article (PubMed ID: 23361084)

  • 81. Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate-to-severe plaque psoriasis: results from EXCEED, a randomized, double-blind head-to-head monotherapy study.
    Gottlieb AB; Merola JF; Reich K; Behrens F; Nash P; Griffiths CEM; Bao W; Pellet P; Pricop L; McInnes IB
    Br J Dermatol; 2021 Dec; 185(6):1124-1134. PubMed ID: 33913511
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis.
    Baeten D; Sieper J; Braun J; Baraliakos X; Dougados M; Emery P; Deodhar A; Porter B; Martin R; Andersson M; Mpofu S; Richards HB; ;
    N Engl J Med; 2015 Dec; 373(26):2534-48. PubMed ID: 26699169
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Early and sustained efficacy with apremilast monotherapy in biological-naïve patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE).
    Nash P; Ohson K; Walsh J; Delev N; Nguyen D; Teng L; Gómez-Reino JJ; Aelion JA;
    Ann Rheum Dis; 2018 May; 77(5):690-698. PubMed ID: 29343507
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT).
    Antoni CE; Kavanaugh A; van der Heijde D; Beutler A; Keenan G; Zhou B; Kirkham B; Tutuncu Z; Burmester GR; Schneider U; Furst DE; Molitor J; Keystone E; Gladman DD; Manger B; Wassenberg S; Weier R; Wallace DJ; Weisman MH; Kalden JR; Smolen JS
    J Rheumatol; 2008 May; 35(5):869-76. PubMed ID: 18381786
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Efficacy and safety results from a Phase 3, randomized, placebo-controlled trial of subcutaneous golimumab in Chinese patients with active rheumatoid arthritis despite methotrexate therapy.
    Li Z; Zhang F; Kay J; Fei K; Han C; Zhuang Y; Wu Z; Hsia EC
    Int J Rheum Dis; 2016 Nov; 19(11):1143-1156. PubMed ID: 26259617
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Efficacy and safety of secukinumab in patients with psoriatic arthritis: A meta-analysis of different dosing regimens.
    Zhang KL; Hou SY; Wu D
    Clinics (Sao Paulo); 2021; 76():e2820. PubMed ID: 34614111
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Secukinumab: IL-17A inhibition to treat psoriatic arthritis.
    Speeckaert R; van Geel N; Lambert J; Claeys L; Delanghe JR; Speeckaert MM
    Drugs Today (Barc); 2016 Nov; 52(11):607-616. PubMed ID: 28112279
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial.
    Nash P; Kirkham B; Okada M; Rahman P; Combe B; Burmester GR; Adams DH; Kerr L; Lee C; Shuler CL; Genovese M;
    Lancet; 2017 Jun; 389(10086):2317-2327. PubMed ID: 28551073
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Pharmacological treatment of psoriatic arthritis: a systematic literature review for the 2015 update of the EULAR recommendations for the management of psoriatic arthritis.
    Ramiro S; Smolen JS; Landewé R; van der Heijde D; Dougados M; Emery P; de Wit M; Cutolo M; Oliver S; Gossec L
    Ann Rheum Dis; 2016 Mar; 75(3):490-8. PubMed ID: 26660203
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Secukinumab in adult patients with lichen planus: efficacy and safety results from the randomized placebo-controlled proof-of-concept PRELUDE study.
    Passeron T; Reinhardt M; Ehst B; Weiss J; Sluzevich J; Sticherling M; Reygagne P; Wohlrab J; Hertl M; Fazel N; Muscianisi E; Fan H; Hampele I; Compagno N
    Br J Dermatol; 2024 Oct; 191(5):680-690. PubMed ID: 38735684
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Achieving remission in psoriatic arthritis by early initiation of TNF inhibition: a double-blind, randomised, placebo-controlled trial of golimumab plus methotrexate versus placebo plus methotrexate.
    van Mens LJJ; de Jong HM; Fluri I; Nurmohamed MT; van de Sande MGH; Kok M; van Kuijk AWR; Baeten D
    Ann Rheum Dis; 2019 May; 78(5):610-616. PubMed ID: 30808625
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Adalimumab improves joint-related and skin-related functional impairment in patients with psoriatic arthritis: patient-reported outcomes of the Adalimumab Effectiveness in Psoriatic Arthritis Trial.
    Gladman DD; Mease PJ; Cifaldi MA; Perdok RJ; Sasso E; Medich J
    Ann Rheum Dis; 2007 Feb; 66(2):163-8. PubMed ID: 17046964
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Comparative efficacy and safety of secukinumab, ixekizumab, and tofacitinib in patients with active psoriatic arthritis showing insufficient response to tumor necrosis factor inhibitors.
    Song GG; Lee YH
    Int J Clin Pharmacol Ther; 2021 Jul; 59(7):511-518. PubMed ID: 33835018
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Efficacy of ustekinumab in biologic-naïve patients with psoriatic arthritis by prior treatment exposure and disease duration: data from PSUMMIT 1 and PSUMMIT 2.
    McInnes IB; Chakravarty SD; Apaolaza I; Kafka S; Hsia EC; You Y; Kavanaugh A
    RMD Open; 2019; 5(2):e000990. PubMed ID: 31565242
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Secukinumab: A Review in Psoriatic Arthritis.
    Shirley M; Scott LJ
    Drugs; 2016 Jul; 76(11):1135-45. PubMed ID: 27299434
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Adalimumab: in psoriatic arthritis.
    Simpson D; Scott LJ
    Drugs; 2006; 66(11):1487-96; discussion 1497-9. PubMed ID: 16906782
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial.
    Mease PJ; Gladman DD; Ritchlin CT; Ruderman EM; Steinfeld SD; Choy EH; Sharp JT; Ory PA; Perdok RJ; Weinberg MA;
    Arthritis Rheum; 2005 Oct; 52(10):3279-89. PubMed ID: 16200601
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3).
    Tanaka Y; Takeuchi T; Tanaka S; Kawakami A; Iwasaki M; Song YW; Chen YH; Wei JC; Lee SH; Rokuda M; Izutsu H; Ushijima S; Kaneko Y; Akazawa R; Shiomi T; Yamada E
    Ann Rheum Dis; 2019 Oct; 78(10):1320-1332. PubMed ID: 31350270
    [TBL] [Abstract][Full Text] [Related]  

  • 99. The Efficacy and Safety of Clazakizumab, an Anti-Interleukin-6 Monoclonal Antibody, in a Phase IIb Study of Adults With Active Psoriatic Arthritis.
    Mease PJ; Gottlieb AB; Berman A; Drescher E; Xing J; Wong R; Banerjee S
    Arthritis Rheumatol; 2016 Sep; 68(9):2163-73. PubMed ID: 27059799
    [TBL] [Abstract][Full Text] [Related]  

  • 100. CNTO6785, a Fully Human Antiinterleukin 17 Monoclonal Antibody, in Patients with Rheumatoid Arthritis with Inadequate Response to Methotrexate: A Randomized, Placebo-controlled, Phase II, Dose-ranging Study.
    Mease PJ; Jeka S; Jaller JJ; Kitumnuaypong T; Louthrenoo W; Mann H; Matsievskaia G; Soriano ER; Jia B; Wang C; Nie J; Hsia E
    J Rheumatol; 2018 Jan; 45(1):22-31. PubMed ID: 29093159
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 38.